A promising biomarker adaptive Phase 2/3 design – Explained and expanded

This short communication concerns a biomarker adaptive Phase 2/3 design for new oncology drugs with an uncertain biomarker effect. Depending on the outcome of an interim analysis for adaptive decision, a Phase 2 study that starts in a biomarker enriched subpopulation may continue to the end without...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Cong, Sun, Linda, Zhang, Xuekui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684793/
https://www.ncbi.nlm.nih.gov/pubmed/38034840
http://dx.doi.org/10.1016/j.conctc.2023.101229
_version_ 1785151486070620160
author Chen, Cong
Sun, Linda
Zhang, Xuekui
author_facet Chen, Cong
Sun, Linda
Zhang, Xuekui
author_sort Chen, Cong
collection PubMed
description This short communication concerns a biomarker adaptive Phase 2/3 design for new oncology drugs with an uncertain biomarker effect. Depending on the outcome of an interim analysis for adaptive decision, a Phase 2 study that starts in a biomarker enriched subpopulation may continue to the end without expansion to Phase 3, expand to Phase 3 in the same population or expand to Phase 3 in a broader population. Each path can enjoy full alpha for hypothesis testing without inflating the overall Type I error.
format Online
Article
Text
id pubmed-10684793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106847932023-11-30 A promising biomarker adaptive Phase 2/3 design – Explained and expanded Chen, Cong Sun, Linda Zhang, Xuekui Contemp Clin Trials Commun Article This short communication concerns a biomarker adaptive Phase 2/3 design for new oncology drugs with an uncertain biomarker effect. Depending on the outcome of an interim analysis for adaptive decision, a Phase 2 study that starts in a biomarker enriched subpopulation may continue to the end without expansion to Phase 3, expand to Phase 3 in the same population or expand to Phase 3 in a broader population. Each path can enjoy full alpha for hypothesis testing without inflating the overall Type I error. Elsevier 2023-11-10 /pmc/articles/PMC10684793/ /pubmed/38034840 http://dx.doi.org/10.1016/j.conctc.2023.101229 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Chen, Cong
Sun, Linda
Zhang, Xuekui
A promising biomarker adaptive Phase 2/3 design – Explained and expanded
title A promising biomarker adaptive Phase 2/3 design – Explained and expanded
title_full A promising biomarker adaptive Phase 2/3 design – Explained and expanded
title_fullStr A promising biomarker adaptive Phase 2/3 design – Explained and expanded
title_full_unstemmed A promising biomarker adaptive Phase 2/3 design – Explained and expanded
title_short A promising biomarker adaptive Phase 2/3 design – Explained and expanded
title_sort promising biomarker adaptive phase 2/3 design – explained and expanded
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684793/
https://www.ncbi.nlm.nih.gov/pubmed/38034840
http://dx.doi.org/10.1016/j.conctc.2023.101229
work_keys_str_mv AT chencong apromisingbiomarkeradaptivephase23designexplainedandexpanded
AT sunlinda apromisingbiomarkeradaptivephase23designexplainedandexpanded
AT zhangxuekui apromisingbiomarkeradaptivephase23designexplainedandexpanded
AT chencong promisingbiomarkeradaptivephase23designexplainedandexpanded
AT sunlinda promisingbiomarkeradaptivephase23designexplainedandexpanded
AT zhangxuekui promisingbiomarkeradaptivephase23designexplainedandexpanded

Ejemplares similares